On the other hand, there is not enough evidence to determine the utility of TLR7/8 as a target for a vaccine adjuvant [15] despite that the TLR7 agonist imiquimod has been licensed as a topical formulation to treat genital warts, actinic keratosis, basal cell carcinoma, and lentigo maligna [72]. Here, TLR7 is linked to anogenital human papillomavirus infection.